Introduction
Gene profiling by microarrays has been shown to be a powerful approach in gene discovery (1, 2) . With the development of congenic strains already trapping quantitative trait loci (QTLs), gene profiling could complement the physical mapping strategy to identify potential candidate genes for QTLs. We have recently mapped multiple QTLs for blood pressure (BP) in a region on Dahl salt-sensitive (S) rat and one segment harboring one QTL on Chr 16. Third, the new congenic strain was utilized to conduct expression profiling studies on rat gene chip microarrays. Finally, potential candidates found from expression profiling were localized to chromosome regions and/or analyzed.
One advantage of creating a combination congenic strain is that it harbored four, instead of only one, QTLs. Assuming that the expressions of these QTLs were not affected by one another, then, a differential expression in any one of the four QTLs should be manifested between S and the combination congenic strain. As a result, we were able to derive the expression profiles for all four QTLs by comparing just two strains, i.e., the S parental strain and the combination congenic strain (using triplicate samples for each strain for a total of six samples). The use of such a combination congenic strain appeared to reduce the costs considerably compared to expression profiling using four separate strains for each of the four QTLs in question, and in triplicates for each strain no less, i.e., a total of 12 (4 3, congenic strains) 3 (S rats) 15 . Thus, a combination congenic strain could be a cost-effective, yet potentially efficient, means of detecting genes differentially expressed in the study of multiple QTLs.
A disadvantage of this approach would be that multiple QTLs may not function with each other in a purely additive fashion. The three QTLs on Chr 10 appeared to act independently of one another (5) . We cannot rule out the possibility that the expressions of these QTLs might interfere with that of the QTL on Chr 16. Such an effect, if present, could have influenced the outcome of the gene profiling.
Methods

Animals
The SS/Jr strain used to establish congenic substrains is designated as S in the present report and is the same as that used in our previous work (3) (4) (5) (6) (7) (8) . In order to ensure that our S rats were not contaminated, a rigorous and strict quality control procedure including genetic testing and examination for physical distinctions was instituted (7, 8) .
Constructions of Congenic Substrains for Fine Mapping a QTL on Chr 16
Two congenic strains, S.L1 and S.L2, that were previously shown to have trapped a BP QTL on Chr 16 were used to initiate fine mapping (6) . For the sake of clarity, these strains were renamed C16S.L1 and C16S.L2 in the current report, in order to indicate that they were made for Chr 16 and represent the congenic strains S.LEW-(D16Mit3-C16Rat112)/Lt and S.LEW-(D16Mit2-D16Chm23)/Lt, respectively. In fine mapping, rats of the S strain were first cross-bred with rats of the C16S.L1 or C16S.L2 strains to produce F1 rats. Brothers and sisters of the F1 rats were intercrossed to produce F2 progeny. The F2 rats were genotyped for markers inside the chromosome segments in question (Fig. 1 ). Rats with crossovers inside the region of interest were searched. Special care was taken to obtain a rat that included a minimum telomeric region.
Because the section harboring the QTL was less than 50 centiRay (CR) (6), only two rats were found. Each of these two rats was then backcrossed (BC) to an S rat to duplicate the fragment. Male and female heterozygous BC rats were intercrossed to derive progeny that were LL homozygous for the region of interest, and homozygous SS for the rest of the chromosome and the rest of the genome. This was verified by genotyping more than 90 markers scattered throughout the rat genome (3, 4, 6) . As a result, two congenic substrains were established. According to the Rules for Nomenclature of Mouse and Rat Strains at (http://www.informatics.jax.org/ mgihome/nomen/strains.shtml congenic), they were designated as S.LEW-(D16Rat38-D16Chm66)/Lt (abbreviated as C16S.L3) and S.LEW-(D16Rat12-D16Chm23)/Lt (abbreviated as C16S.L4), respectively. The chromosome region homozygous LL in each strain is indicated by a solid bar in Fig.  1 . All the markers in the region were genotyped for each congenic strain in question and were homozygous LL. Their BP data are presented in Fig. 2 .
New Congenic Combination between Chrs 10 and 16
For the convenience of presentations, a congenic strain from a chromosome is marked by the prefix C10, indicating Chr 10, and C16, indicating Chr 16. The congenic strain for Chr 10, previously named S.LC10 (5), is here re-designated C10S.L. The desired combination congenic strain will be abbreviated as C10S.L/C16S.L2 for S.LEW-(D10Rat119-D10Mgh1);(D16Rat21/D16Rat112)/Lt. C10S.L is the abbreviation for S.LEW-(D10Rat119-D10Mgh1)/Lt and C16S.L2 is the abbreviation for S.LEW-(D16Mit2-D16Chm23)/Lt.
The chromosome fragments involved in making the combination congenic strain, C10S.L/C16S.L2, are schematically represented in Fig. 3 . In making the strain, rats of the C10S.L strain were crossed to rats of the C16S.L2 strain to produce F1 rats, which were then intercrossed to produce F2. Among F2 rats, regions of interest were genotyped for the selection of the rats homozygous LL for the markers involved in both the C10S.L and C16S.L2 regions. These regions are indicated by solid bars in Fig. 3 . All the markers in the region were genotyped and were homozygous LL. The resulting rat strain represents the combination congenic strain C10S.L/C16S.L2. The rest of Chrs 10 and 16 and the rest of the genome were found to be homozygous SS by a genomic scan using over 90 markers scattered throughout the rat genome as reported previously (3, 4, 6) . Table 1 shows new markers produced.
Protocols for handling and maintaining animals were approved by our institutional animal committee. All the procedures for the experiment were in accordance with the guidelines of institutional, provincial and federal regulations.
BP Measurements
The BPs of rats were measured essentially as described previously (3) (4) (5) (6) (7) (8) . In brief, mating pairs of the S and one of the congenic strains listed in Fig. 1 were bred simultaneously. Male rats were weaned at 21 days of age, maintained on a low salt diet (0.2% NaCl, Harlan Teklad 7034) and then fed a high salt diet (2% NaCl, Harlan Teklad 94217) starting from 35 days of age until the end of the experiment. The implantation of telemetry probes and the postoperative care of animals were as described previously (7, 8) . A telemetry system from Data Sciences Inc. (St. Paul, USA) was used to measure BP. Each telemetry probe was calibrated before and cleaned after each use according to the manufacturer's instructions.
Statistical Analysis
Repeated measures analysis of variance (ANOVA) followed by Dunnett's correction using the SYSTAT 9 program (SPSS Sciences, Chicago, USA) was used to compare the significance of differences in a BP component between the congenic and S strains. The Dunnett correction takes into account group comparisons as well as sample sizes among the groups compared.
Gene Profiling
The important consideration is that there is always a compromise between studying multiple tissues and multiple congenic strains at multiple time points vs. the cost of chips and the desirability of having multiple data sets. Our goal is to find genes that are differentially expressed between S and LEW and that are located on Chrs 10 and 16.
Animals
Age-matched S and C10S.L/C16S.L2 rats were chosen. Only male rats were used to avoid fluctuating effects of female hormones. Since renal hypertrophy has previously been associated with BP effects of certain QTLs in question (4, 6) , the kidneys were selected to conduct the microarray analysis. The age of the rats was 5 weeks because genes differentially expressed would have a better chance of being causal rather than consequential to hypertension. This consideration differs from our BP studies in the age of the animals, because in that case a full-blown hypertension is needed for BP compar- cgaccagtgtaggggattgt/ggtttcctgctccctaatcc 158 60 P S<L S, Dahl salt-sensitive strain; L, Lewis strain; P, polyacrylamide; A, agarose; bp, base pairs. The supercontig NW_043030 is obtained from blasting an existing marker on the map (Fig. 1) on the rat genome database at http://www.ncbi.nlm.nih.gov/genome/seq/ RnBlast.html. isons above. The rats used for the gene profiling studies were fed a 2% NaCl diet starting at 4 weeks of age. In the BP studies above, the age of the rats at the end of the experiments was 14 weeks.
C10S.L refers to the S.LEW-(D10Rat119-D10Mgh1)/ Lt congenic strain; C16S.L2 refers to the S.LEW-(D16Rat 21-D16Rat112)/Lt congenic strain; C10S.L/C16S.L2 refers to the combination S.LEW-(D10Rat119-D10Mgh1);(D16Rat21-D16Rat112)/Lt congenic strain. The genes/ESTs are from
RNA Preparations
For profiling, 5-week-old male rats of the S and C10S.L/ C16S.L2 strains were sacrificed by decapitation. Total RNAs were prepared from the kidneys of each rat using a RNeasy kit from Qiagen (Mississauga, Canada). Then, kidney RNAs from the two rats of each strain were pooled to minimize within strain variations. A total of 6 rats for the S and 4 rats for the C10S.L/C16S.L2 congenic strain were used, i.e., three independent pools of S containing 2 rats in each pool and two independent pools of C10S.L/C16S.L2 containing 2 rats in each pool. Thus, the whole experiment represented independent triplicate samples for the S strain and duplicate samples for C10S.L/C16S.L2 strains.
Chip Experiments
Rat chips of the U34 series (i.e., A, B, and C) from Affymetrix (http://www.affymetrix.com) were used for comparisons between the S and the C10S.L or C16S.L2 strains. Each chip contains approximately 8,700 genes/ESTs.
The following chip work was done at the Montreal Genome center by a fee-for service arrangement (http://genome.mcgill.ca/). In brief, to begin, 10 µg of total RNA was dissolved in 10 µl of nuclease-free water, and 1 µl (100 pmol) of T7-(T) 24 primer (Genosys, 5 -GGCCAGT GAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-3 ) was added. The primer-RNA mixture was denatured for 10 min at 70ºC, then chilled on ice. First strand cDNA synthesis was carried out using 2 µl of Superscipt II reverse Transcriptase (invitrogen life technologies, Carlsbad, USA) in a 20 µl reaction buffer containing 10 µmol/l DTT, 500 µmol/l of each dNTP, and 1 First Strand Buffer (Invitrogen Life Technologies) for 60 min at 42 ºC. The following second strand synthesis was carried out by adding 40 U DNA Polymerase I (Invitrogen Life Technologies), 10 U Escherichia coli DNA ligase (Invitrogen Life Technologies) and 2 U RNAse H (MBI Fermentas, Burlington, USA) in a final volume of 150 µl containing 1 second strand buffer (Invitrogen Life Technologies). For the purpose of creating blunt ends, 10 units of T4 Polymerase (MBI Fermentas) were added and allowed to react for 2 h at 16 ºC, then stopped by adding 10 µl of 0.5 mol/l EDTA (Sigma, St. Louis, USA).
cDNAs were purified by phenol chloroform extractions using Phase-Lock tubes (Eppendorf), then precipitated and redissolved in 20 µl of the nuclease-free water. A biotinylated probe was made from the cDNA reaction mixture using the ENZO Bioarray High Yield RNA Transcript Labeling Kit (ENZO Diagnostics, Farmingdale, USA) by the protocol specified by the supplier. The synthesis was carried out at 37 ºC for 5 h with occasional agitations. The labeled cRNA was then purified using an RNeasy total RNA clean up kit with spin columns (Qiagen), and eluted in 60 µl of the nuclease-free water. (An aliquot of the purified cRNA was analyzed on RNA 6000 Nano LabChip (Agilent, Mississauga, Canada) to ascertain the integrity and size distributions). Twenty µg of cRNA was fragmented by heating at 94 ºC for 35 min in 1 fragmentation buffer (40 mmol/l Tris-acetate (Ac) pH 8.1; 100 mmol/l KOAc; 30 mmol/l MgOAc).
For hybridization, a mixture was prepared by adding 15 µg of the biotinylated probe, Control Oligonucleotide B2 (final concentration: 50 pmol/l; Affymetrix, Santa Clara, USA), herring sperm DNA (final concentration 0.1 mg/ml, Invitrogen Life Technologies), and acetylated BSA (final concentration: 0.5 mg/ml; Invitrogen Life Technologies) in a final volume of 300 µl of 1 MES hybridization buffer (100 mmol/l MES, 1 mol/l NaCl, 20 mmol/l EDTA, 0.01% Tween-20; Sigma). The hybridization mixture was denatured for 5 min at 100 ºC, incubated for 5 min at 45 ºC and microfuged for 5 min. The microarray was warmed to room temperature and prehybridized in 1 hybridization buffer for 10-20 min at 45 ºC. Then, the prehybridization buffer was replaced with 200 µl of the hybridization mix. Hybridization was performed at 45 ºC overnight (16-20 h) in a rotating oven (Affymetrix) at 60 rpm.
After hybridization, the chip was immediately placed in the Affymetrix GeneChip Fluidics Station 400 (Affymetrix, Santa Clara, USA), followed by 10 low-stringency washes (6 SSPE, 0.01% Tween-20, 0.005% Antifoam) and 4 highstringency washes (100 mmol/l MES, 0.1 mol/l NaCl, 0.01% Tween-20, 50ºC; Sigma). Bound probes were incubated with streptavidin phycoerthryin (SAPE; Molecular Probes, Eugene, USA), followed by 10 low-stringency washes. The array was incubated with a biotinylated anti-streptavidin antibody (Vector Laboratories, Burlingame, USA) and cleaned again with 15 low-stringency washes. Specifically bound probes were detected using an Agilent GeneArray Scanner 2500 (Affymetrix). The scanned images were analyzed using the Microarray Analysis Suite software, version 5.0 (Affymetrix) in order to identify the presence and intensities of the genes/Established Sequence Tags (ESTs) expressed. Statistical analyses were done with the Kensington Discovery Edition software, version 1.8 (InforSense, London, UK). Normalizations of data across the chips and threshold establishments for differentially expressed genes were performed as described previously (9) . Consequently, a fold difference or a ratio of 2.5 for a gene/EST between the congenic and S strains was taken as the cut-off. Genes located in the chromosome regions of interest were reexamined regardless of fold differences. Those genes that were significantly differentially expressed between S and C10S.L/C16S.L2 were selected.
Mapping of Differentially Expressed Genes/ESTs
Genes/ESTs in Table 1 were localized onto the new physical map by a combination of the in silico methods described at the following web addresses: http://ratest.eng.uiowa.edu/cgibin/database/search, http://rgd.mcw.edu/RHMAPSERVER/, http://www.ncbi.nlm.nih.gov/UniGene/ and http://www.ncbi.nlm. nih.gov/BLAST/.
Verification of Differential Gene Expressions by Real Time Reverse Transcription (RT)-Polymerase Chain Reaction (PCR)
The LC-RNA Master SYBR Green I kit (Cat. 3064760; Roche Diagnostics, Basel, Switerland) was used on the Sun Light Cycler according to the manufacturer's instructions. Experimental conditions were determined by varying the concentrations of primers and Mn(OAc)2 as well as the temperatures. These conditions were determined for both the internal standard of a house keeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the gene/EST of Rn.42273 unknown EST, no homology C10S.L/C16S.L2 is the combination congenic strain that contains 4 QTLs as depicted in Fig. 3 . Fold difference (fold diff) represents a ratio between C10S.L/C16S.L2 and S for the normalized expression for that gene/EST. Only the ESTs/genes with fold diff above 2.5 are given. A ' ' sign in fold diff signifies that the expression level for the gene/EST is under-expressed in the congenic strain compared to that of the S strain. A total of 6 rats for the S and 4 rats for the C10S.L/C16S.L2 congenic strain were used, i.e., three independent pools of S containing 2 rats in each pool and two independent pools of C10S.L/C16S.L2 containing 2 rats in each pool. Thus, the whole experiment represented independent triplicate samples for the S and duplicate samples for the C10S.L/C16S.L2 strains. The names of the contigs, in which ESTs/genes are found, start with NW_ followed by 5 digit numbers and are in the last column. The expression information has been deposited at geo@ncbi.nlm.nih.gov. Accession numbers are given from GSM6103 to GSM6117 plus DSE413. Those located on Chrs 10 and 16 are in italics, and their chromosome locations are shown in Figs. 1 and 3 . QTLs, quantitative trait loci; S, Darl salt-sensitive; EST, established sequence tags.
interest. The primers for the standard GAPDH (Genebank accession no. AF106860) were forward 5 -atgggaagctggtcatcaa c-3 and reverse 5 -gtggttcacacccatcacaa-3 . The RT-PCR reaction for GAPDH was performed using 0.5 µmol/l of primer and 3.25 mmol/l [Mn(OAc)2] at 60°C. Melting curve analysis was performed to make sure there was only one product. Standard curves were made using triplicate RNA samples of the rat strains of interest for both GAPDH and the unknown gene/EST with a series of dilutions (10, 10 2 , 10 3 , 10 4 , 20 4 ). The quantification of the gene/EST concentration was calculated as a ratio to GAPDH based on the standard curves. The LightCycler Relative Quantification Software (Roche Diagnostics, Basel, Switerland) was used to obtain the normalized ratio as a final result.
Results
Production of New Chr 16 Markers
Supercontigs located in the Chr 16 regions of interest were first identified by blasting with a known marker at the website: http://www.ncbi.nlm.nih.gov/genome/seq/RnBlast.html (Fig. 1) . In these supercontigs, regions containing microsatellites were searched, and when found, were used to design markers for genotyping rats based on PCR. According to the guidelines on the rat nomenclature (http://rgnc.gen.gu.se/Brief.html), these new markers were designated with D16Chm prefixes, which represent the institutional origin of the markers, i.e., Centre Hospitalier de l'Université de Montreal (CHUM). Only those that gave workable PCR products are listed in Table 1 .
BP Studies
All the BP components were measured, including mean (MAP), diastolic (DAP) and systolic (SAP) arterial pressures. For the simplicity of presentation, each point in the graphs in Fig. 2 represents averaged 6-h readings taken from every 2 min. One BP reading was taken every 2 min for the period of measurement. Then, these readings were averaged for 6 h to obtain one data point, which appears as a point on the graph. Please see Dutil and Deng (8) for detailed comparisons of BPs of S and a congenic strain showing even finer reading variations during our typical BP measurements.
BPs for all the strains shown in Fig. 2 were measured at least at two different times, i.e., they were separate litters raised at various time points during a period of several months. The results showed that BPs for each strain were not different during the separate periods of measurements. Therefore, the BP data were pooled from reproducible measurements for each strain (Fig. 2) .
Fine QTL Mapping on Chr 16
As shown in Fig. 2 , MAP, DAP and SAP of C16S.L2 ( Fig.   1 ) were significantly lower than those of S ( p<0.01). MAPs, DAPs and SAPs of C16S.L3 and C16S.L4 were not different from that of S ( p>0.4). These results are summarized at the bottom of Fig. 1 .
Genes/ESTs Found by Gene Profiling
Microarrays on a genome-wide expression profiling of the rat detected a total of 67 genes expressed in the chromosome region of C10S.L (Fig. 1) . Not many genes were found in the chromosome region of C16S.L2 (Fig. 1) , probably due to the fact it is close to the telomere. The expression information has been deposited at geo@ncbi.nlm.nih.gov. Accession numbers are those from GSM6103 to GSM6117 plus DSE413.
On the whole, 27 (Table 2) out of approximately 26,100 genes/ESTs were potentially differentially expressed candidates. Of these 27, 6 (i.e., 22%) genes/ESTs are located on Chr 10, 1 (0.4%) was on Chr 16, 2 (7%) had multiple chromosome locations including Chr 10, 15 (56%) were located on other chromosomes and 3 (11%) were not localized, but probably fall into genomic regions yet to be sequenced in the rat genome project.
To confirm the differential expression of genes, RT-PCR was used. Only the expression of Rn.16843 taken from Table 2 was proven to be different (data not shown); and the rest of the genes/ESTs have not been verified. The 6 potential candidates on Chr 10 ( Fig. 3 ) and 1 potential candidate on Chr 16 ( Fig. 1) were placed on the physical map. It turned out that none of these candidates on Chrs 10 and 16 fell inside the intervals harboring the BP QTLs. Five of 6 on Chr 10 were located in the region between C10QTL2 and C10QTL3, and 1 of 6 was below C10QTL2 on the map (Fig.  3) . Rn.13534 was found to be above C16QTL (Fig. 1) . Consequently, no further work of verifications by either Northern or RT-PCR was pursued on these genes/ESTs.
Discussion
The novel findings of the current study were that the C16QTL was further narrowed and genes from expression profiling were identified and placed on Chrs 10 and 16.
Congenic Strains as a Means of QTL Fine Mapping
Among the three congenic strains, C16S.L2, C16S.L3 and C16S.L4, only C16S.L2 had a BP effect (Fig. 2) . Consequently, the BP QTL has to be localized to the interval between the D16Chm66 and D16Rat12 markers (Fig. 1) . A congenic strain involving only this interval will definitely prove this is true.
Because the C16S.L4 congenic strain did not show a BP effect (Fig. 2) , the telomeric region defined by it can be ruled out as having a primary effect on BP (Fig. 1) . Although the distance among the markers located in the segment of D16Mit2 and D16Chm23 showed 0 cR, the physical distance is more than 3.4 megabases (Fig. 1) . Thus, in the pursuit of QTL identification, the physical distance is a more accurate and useful means of gauging how far two markers are apart.
Gene Profiling in Finding Candidates for QTLs
Microarrays held tremendous promise when they emerged as a gene discovery tool (1) . They seemed to offer a quick and efficient route to circumvent the time consuming and labor intensive work of fine physical mapping. However, our present work lends further credence to the notion that the results of gene profiling must be supported by fine QTL mapping if one is to identify a QTL by this method (2) . Even though their secondary effects on BP can not be ruled out at the present, the genes/ESTs identified from our profiling experiments were not primary candidates for QTLs, because they were not located in the QTL-intervals on Chr 10 ( Fig. 3) or on Chr 16 ( Fig. 1) . Interestingly, Okuda and coworkers also found that most of the differentially expressed genes between spontaneously hypertensive rats (SHR) and WistarKyoto rats (WKY) could not be associated with hypertension (10) .
A caveat of the present gene profiling work is that it was limited to kidneys of 5-week-old male rats on a 2% salt diet for 1 week starting from 4 weeks of age. It is expected that gene expressions would be different at other developmental stages (e.g., at the prenatal stage and at different ages after birth), under different environmental conditions (e.g., on a low or varying salt diet), and/or in different tissues (e.g., in the heart, left ventricals, adrenals, brain, and lungs). Also, the current chip work did not preclude any false negatives, i.e., genes differentially expressed but undetected, either because their levels of expression were too low, or the 2.5-fold cutoff was set too high. On the other hand, these genes except Rn.16843 listed in Table 2 may not be truly differentially expressed, predicating on more stringent confirmations by either real time RT-PCR or Northerns.
There are other limitations in our current expression profiling work. First, the commercially available rat chips do not contain all the genes. This lack of coverage impedes the study of genes, and especially of those genes located in the regions harboring the QTLs of interest in the present study. As fine chromosome mapping progresses, a focused expression profiling seems more profitable, e.g., a profiling based on customer-region-specific microarrays. In that case, multiple tissues could be tested on all those genes located in the regions harboring QTLs (Figs. 1 and 3 ), but not yet placed on rat chips commercially. Second, a LEW control might give some useful information.
It is interesting to note that more than half of the genes/ESTs were outside Chrs 10 and 16 or in unknown locations ( Table 2 ), considering that genome differences between S and C10S.L/C16S.L2 should be mostly in the segments on Chrs 10 and 16 in question (Fig. 3) . These genes or ESTs on the other chromosomes were differentially expressed in our congenic and S strain comparisons probably due to one or a combination of several factors. First, there could be a secondary effect of a regulatory cascade transmitting from a gene located in the congenic region on Chrs 10 and 16. Second, any remaining heterozygosity of the LEW genome in the chromosome segments outside the congenic regions could contain the genes or influence their expressions. Third, during congenic constructions, chromosome reshuffling between the LEW and S genomes in certain regions could affect these gene expressions in the congenic strain. That is, there were crossovers throughout chromosomes during meiosis. If it so happened that one regulatory region from the S (or LEW) allele that would affect gene expressions was juxtaposed into the coding region of the homologous gene of the LEW (or S) allele during this crossover, the expression of the 'chimeric' gene might be altered as a consequence. Our results are consistent with the observations of other investigators, who also found that most of their differentially expressed genes were not located on the targeted chromosomes (11, 12) .
Comparative QTL Mapping
The QTLs on Chr 10 ( Fig. 3) have great potentials relevance to certain forms of human genetic hypertension (13) (14) (15) . Mutations in one of the genes for WNK kinases were found to be responsible for the Gordon syndrome, a rare form of human hypertension (16) . It is not likely, though, that Wnk4 would be a candidate for one of the QTLs on Chr 10, because it is located between D10Rat207 and Brca1. This interval is above QTL2 and below QTL3 regions (Fig. 3) .
Nevertheless, the homology mapping among the rat, mouse and humans offers the promise of new QTL discoveries. The combination of fine chromosome fine mapping and new genomic technologies certainly will hold the key to identifying genes for BP QTLs (17, 18) .
